Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

August 30, 2023

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

Presentation ESC 2022

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

Presenter: Sanjit Jolly

August 28, 2022

More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

September 03, 2020

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

Medically Ill Pa+ent Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presentation ESC 2018

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presenter: Alex C. Spyropoulos

August 27, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Presentation ESC 2017

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Presenter: John Eikelboom

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

News Conference News ESC 2016

Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4

August 31, 2016

News Conference News ESC 2016

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Michael O'Riordan

August 28, 2016

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.